Form 4: ClearPoint Neuro CEO Joseph Burnett Reports Share Disposition for Tax Obligations

ClearPoint Neuro, Inc. CEO and President Joseph Burnett reported the disposition of 15,476 shares of common stock to cover tax withholding obligations related to restricted stock vesting.

Summary

• Joseph Burnett, who serves as CEO and President, and a Director of ClearPoint Neuro, Inc. (CLPT), filed a Form 4 with the SEC.
• The filing details a transaction on June 10, 2025, involving the disposition of 15,476 shares of ClearPoint Neuro Common Stock.
• These shares were disposed of at a price of $13.29 per share.
• The purpose of this disposition was to satisfy applicable tax withholding obligations in connection with the vesting of restricted stock.
• Following this transaction, Joseph Burnett directly holds 9,887 shares and indirectly holds 243,522 shares through the Joseph M. Burnett Trust dated October 20, 2022.

Sentiment

Score: 5

Explanation: The document reports a routine, non-discretionary insider transaction (tax withholding on restricted stock vesting). It is neutral in terms of company performance or strategic direction.

Positives

• The reported transaction is a non-discretionary disposition of shares for tax withholding purposes, which is a routine event upon the vesting of restricted stock and does not indicate a lack of confidence in the company by the insider.

Negatives

• The transaction results in a reduction of 15,476 shares from the CEO's direct beneficial ownership, although this is for tax purposes rather than a discretionary sale.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The filing indicates that the disposition of shares was to 'satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.'

Industry Context

This Form 4 filing is a routine insider transaction report and does not provide information relevant to broader industry trends or competitive analysis for the medical device or neuro-navigation industry.

Comparison to Industry Standards

• This document is a standard insider transaction report (Form 4) and does not contain financial or operational data that can be compared to industry benchmarks or specific comparable companies/projects.

Related Party Transactions

• Joseph M. Burnett indirectly owns 243,522 shares through the Joseph M. Burnett Trust dated 10/20/2022, where he serves as trustee.

Stakeholder Impact

• Shareholders: The transaction represents a minor, non-discretionary reduction in the CEO's direct shareholding, which is a common occurrence for vested restricted stock and is unlikely to significantly impact shareholder perception.

Key Dates

Keywords

ClearPoint Neuro, CLPT, Joseph Burnett, Form 4, Insider Transaction, Stock Vesting, Tax Withholding, Beneficial Ownership, SEC Filing